This letter was authored by Breakthrough T1D Canada President and Chief Executive Officer Jessica Diniz. She is cosigning this letter with eight individuals working in health and research. It was published in Le Devoir on February 26, 2026. In Quebec, thousands of adults living with type 1 diabetes (T1D) face a persistent and unjustified inequity in access to […]
UPDATE: January 5, 2026 – Canada’s Drug Agency has just announced a decision not to reimburse Tzield (teplizumab) In Canada, reimbursement of therapeutics is based on recommendations from Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS). Applications for reimbursement review of Tzield (teplizumab) – the first disease-modifying […]
The following Op Ed was co-authored by Breakthrough T1D’s President and CEO, Jessica Diniz and Cate Murray, President and CEO of the Stem Cell Network and was published in the Hill Times on October 30. — From insulin to regenerative therapy, Canada’s contribution to diabetes research is unmatched. The question is whether we’ll continue to […]